Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06708572
NA

Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia

Sponsor: National Liver Institute, Egypt

View on ClinicalTrials.gov

Summary

The aim of the study is to evaluate the use of Granulocyte Colony Stimulating Factor (GCSF) on the clinical and biochemical outcome of type 3 biliary atresia post kasai.

Key Details

Gender

All

Age Range

20 Days - 1 Year

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2024-12

Completion Date

2026-10-30

Last Updated

2024-12-11

Healthy Volunteers

Yes

Interventions

DRUG

Granulocyte Colony-Stimulating Factor

20 patients will receive subcutaneous GCSF at a daily dose of 10ug/kg for 3 consecutive days. It is administered within 3-4 days after the Kasai procedure.

Locations (1)

National Liver Institute

Cairo, Menofia Governorate, Egypt